Position in ROIV
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$76,182,954
+$16,554,023 QoQ
Shares Held
2,152,669
0.0% QoQ
Ownership
0.298%
of shares outstanding
% of Portfolio
1.95%
of 13F equity value
Holder Rank
#47
of 494 holders
Holding Since
Mar 2024
10 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ROIV Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026DME Capital Management, LP holds $109,269,925 across 6 Biotechnology names. ROIV ranks #1 (69.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ROIV |
Roivant Sciences Ltd.
This page
|
2,152,669 | $76,182,954 | |
| 2 | LKFT |
Lakefront Biotherapeutics NV
|
482,746 | $14,472,724 | |
| 3 | COYA |
Coya Therapeutics, Inc.
|
2,335,540 | $13,662,908 | |
| 4 | IMVT |
Immunovant, Inc.
|
93,520 | $3,603,325 | |
| 5 | GANX |
Gain Therapeutics, Inc.
|
566,130 | $1,149,243 | |
| 6 | NUVB |
Nuvation Bio Inc.
|
34,995 | $198,771 |
All Filings in ROIV
Export CSV
10 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $76,182,954 | 2,152,669 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $59,628,931 | 2,152,669 | Shares | Other | 2026-05-15 | |
| 2025-12-31 | $44,904,005 | 2,069,309 | Shares | Other | 2026-02-17 | |
| 2025-09-30 | $34,428,752 | 2,275,529 | Shares | Other | 2025-11-14 | |
| 2025-06-30 | $51,290,411 | 4,551,057 | Shares | Other | 2025-08-14 | |
| 2025-03-31 | $54,901,374 | 5,441,167 | Shares | Other | 2025-05-15 | |
| 2024-12-31 | $62,356,721 | 5,271,067 | Shares | Sole | 2025-02-14 | |
| 2024-09-30 | $61,254,781 | 5,308,040 | Shares | Other | 2024-11-14 | |
| 2024-06-30 | $50,851,847 | 4,810,960 | Shares | Other | 2024-08-14 | |
| 2024-03-31 | $44,167,764 | 4,190,490 | Shares | Other | 2024-05-15 | |
| No filing history on record for this holder in this stock. | ||||||